Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HER2/neu peptide vaccine GLSI-100

A cancer peptide vaccine comprised of the epitope GP2, a nine amino acid peptide (amino acids 654-662) derived from the tumor-associated antigen (TAA) HER2/neu (ErbB-2) and the immune-adjuvant granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the HER2/neu peptide vaccine GLSI-100, GP2 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER2/neu antigen, which may result in the inhibition of proliferation of HER2/neu-expressing tumor cells. HER2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF enhances the CTL-mediated immune response against HER2/neu.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:GP2 peptide/GM-CSF GLSI-100
HER2/neu peptide GP2/GM-CSF GLSI-100
peptide vaccine GLSI-100
Code name:GLSI 100
GLSI-100
GLSI100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search